Autopsy and Case Reports
Autopsy and Case Reports
Original Article

Immunohistochemical expression of plasminogen activator inhibitor-1 in subcutaneous versus omental adipose tissue in patients after elective abdominal surgery

Mehmet Yildiz; Emine Bozkurtlar; Abdulmunir Azizy; Mehmet Agirbasli

Downloads: 0
Views: 956


Plasminogen activator inhibitor-1 (PAI-1) is a biomarker of thrombosis. Adipose and vascular tissues are among the major sources of PAI-1 production. Previous studies indicated that fat deposits mediate increased cardiovascular risk among obese individuals. We investigated the immunohistochemical (IHC) expression of PAI-1 in adipose and vascular tissues from the omentum and the subcutaneous tissue. The pathology samples were selected from 37 random patients who underwent elective abdominal surgery between 2008-2009. PAI-1 expression was semi-quantitatively scored and compared between the groups. Significant differences were noted in the IHC expression of PAI-1 between the omental and the subcutaneous adipose tissues (1.1 ± 0.8 versus 0.8 ± 0.6, respectively (p=0.05)). Adipose tissue displayed higher IHC expression of PAI-1 compared to vascular wall tissue in both omentum and subcutaneous sections (1.1 ± 0.8 versus 0.5 ± 0.9 (p=0.004), and 0.8 ± 0.6 versus 0.4 ± 0.6 (p=0.003), respectively). In conclusion, our study compared PAI-1 expression in the omentum versus the subcutaneous tissue and adipose versus vascular tissues. IHC expression of PAI-1 level was significantly higher in the omental adipose tissue compared to the subcutaneous adipose tissue. Adipose tissue displayed significantly higher PAI-1 expression than vascular tissue. The study elucidates the biological differences of adipose and vascular tissue from subcutaneous versus omental sections.


Adipose Tissue, Immunohistochemistry, Plasminogen Activator Inhibitor-1


Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.


Cardiovasc Ther. 2010;28(5):e72-91. []. [PMID:20626406]


Tsantes AE, Nikolopoulos GK, Bagos PG, Bonovas S, Kopterides P, Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk.



Thromb Res. 2008;122(6):736-42. []. [PMID:17949795]


Kolev K, Machovich R. Molecular and cellular modulation of fibrinolysis.



Thromb Haemost. 2003;89(4):610-21. []. [PMID:12669114]


Agirbasli M. Pivotal role of plasminogen-activator inhibitor 1 in vascular disease.



Int J Clin Pract. 2005;59(1):102-6. []. [PMID:15707473]


Barnard SA, Pieters M, De Lange Z. The contribution of different adipose tissue depots to plasma plasminogen activator inhibitor-1 (PAI-1) levels.



Blood Rev. 2016;30(6):421-9. []. [PMID:27233154]


Abraham TM, Pedley A, Massaro JM, Hoffmann U, Fox CS. Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors.



Circulation. 2015;132(17):1639-47. []. [PMID:26294660]


Poirier P, Després J-P. Waist circumference, visceral obesity, and cardiovascular risk.



J Cardiopulm Rehabil. 2003;23(3):161-9. []. [PMID:12782898]


Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study.



Circulation. 2007;116(1):39-48. []. [PMID:17576866]


Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.



Circulation. 1998;97(22):2213-21. []. [PMID:9631870]


Yamamoto K, Takeshita K, Kojima T, Takamatsu J, Saito H. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly.



Cardiovasc Res. 2005;66(2):276-85. []. [PMID:15820196]


Landin K, Stigendal L, Eriksson E, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1.



Metabolism. 1990;39(10):1044-8. []. [PMID:2215252]


Giltay EJ, Elbers JM, Gooren LJ, et al. Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration.



Arterioscler Thromb Vasc Biol. 1998;18(11):1716-22. []. [PMID:9812909]


Cigolini M, Targher G, Andreis IAB, Tonoli M, Agostino G, De Sandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men.



Arterioscler Thromb Vasc Biol. 1996;16(3):368-74. []. [PMID:8630661]


Mertens I, Van Gaal LF. Visceral fat as a determinant of fibrinolysis and hemostasis.



Semin Vasc Med. 2005;5(1):48-55. []. [PMID:15968580]


Atzmon G, Yang XM, Muzumdar R, Ma XH, Gabriely I, Barzilai N. Differential gene expression between visceral and subcutaneous fat depots.



Horm Metab Res. 2002;34(11-12):622-8. []. [PMID:12660871]


Miyazawa-Hoshimoto S, Takahashi K, Bujo H, Hashimoto N, Saito Y. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects.



Diabetologia. 2003;46(11):1483-8. []. [PMID:14534780]


Cigolini M, Tonoli M, Borgato L, et al. Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha?



Atherosclerosis. 1999;143(1):81-90. []. [PMID:10208482]


Gottschling-Zeller H, Birgel M, Röhrig K, Hauner H. Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture.



Metabolism. 2000;49(5):666-71. []. [PMID:10831181]


Bastelica D, Morange P, Berthet B, et al. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits.



Arterioscler Thromb Vasc Biol. 2002;22(1):173-8. []. [PMID:11788479]


Van Harmelen V, Hoffstedt J, Lundquist P, et al. Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals.



Thromb Haemost. 2000;83(4):545-8. []. [PMID:10780314]


He G, Pedersen SB, Bruun JM, Lihn AS, Jensen PF, Richelsen B. Differences in plasminogen activator inhibitor 1 in subcutaneous versus omental adipose tissue in non-obese and obese subjects.



Horm Metab Res. 2003;35(3):178-82. []. [PMID:12734779]


Hardy OT, Perugini RA, Nicoloro SM, et al. Body mass index-independent inflammation in omental adipose tissue associated with insulin resistance in morbid obesity.



Surg Obes Relat Dis. 2011;7(1):60-7. []. [PMID:20678967]


O’Connell J, Lynch L, Cawood TJ, et al. The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity.



PLoS One. 2010;5(4):e9997. []. [PMID:20376319]


Yang Y-K, Chen M, Clements RH, Abrams GA, Aprahamian CJ, Harmon CM. Human mesenteric adipose tissue plays unique role versus subcutaneous and omental fat in obesity related diabetes.



Cell Physiol Biochem. 2008;22(5-6):531-8. []. [PMID:19088435]


Harman-Boehm I, Blüher M, Redel H, et al. Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity.



J Clin Endocrinol Metab. 2007;92(6):2240-7. []. [PMID:17374712]


Vaughan DE. PAI-1 and TGF-beta: unmasking the real driver of TGF-beta-induced vascular pathology.



Arterioscler Thromb Vasc Biol. 2006;26(4):679-80. []. [PMID:16556860]


Sato O, Ashizawa N, Ohtsuru A, et al. Fibrotic response to angiotensin II is blunted in the kidney, but not in the heart, in insulin-sensitive long-lived transgenic dwarf rats.



Int J Mol Med. 2007;19(1):23-7. []. [PMID:17143544]




































































Publication date:

5d9238490e88258c1652d4d2 autopsy Articles
Links & Downloads

Autops Case Rep

Share this page
Page Sections